|Bid||186.73 x 800|
|Ask||201.71 x 800|
|Day's Range||193.73 - 197.13|
|52 Week Range||181.22 - 262.00|
|Beta (5Y Monthly)||1.34|
|PE Ratio (TTM)||20.50|
|Earnings Date||Aug 01, 2023 - Aug 07, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||249.00|
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
It is hard to get excited after looking at Charles River Laboratories International's (NYSE:CRL) recent performance...
Q1 2023 Charles River Laboratories International Inc Earnings Call
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
Charles River Laboratories International Inc beat Wall Street estimates for first-quarter profit on Thursday, due to strong demand for its services that help clients discover new drug candidates and assess their safety. The contract research company reported revenue of $662.4 million in its discovery and safety assessment (DSA) segment, higher than analysts' average estimate of $610.9 million, according to Refinitiv data. Wilmington, Massachusetts-based Charles River said it believes its biotech clients have the funds required to take the development of their drug candidates forward, pointing to the robust demand for its DSA unit services.
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, Mass., May 11, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9 million in the first quarter of 2022.
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
WILMINGTON, Mass., May 01, 2023--Charles River launches Accugenix NGS for bacterial identification and fungal ID; announces partner lab initiative to expand global coverage.
WILMINGTON, Mass., April 11, 2023--Charles River Laboratories Schedules First-Quarter 2023 Earnings Release and Conference Call
WILMINGTON, Mass., April 10, 2023--Charles River highlights the importance of next-generation technologies for oncology drug discovery at AACR 2023.
Key Insights Charles River Laboratories International's estimated fair value is US$212 based on 2 Stage Free Cash Flow...
The board of Charles River Laboratories has unanimously recommended against a shareholder proposal requiring transparency on its import practices of lab monkeys, according to a regulatory filing by the U.S. contract research organization firm. The proposal, brought forward by animal rights non-profit PETA, suggests Charles River annually disclose the species and the country of origin of the non-human primates (NHP) that it imports into the United States as a part of animal research services it offers to drug developers. PETA's proposal also demands information on whether the monkeys are caught in the wild or bred in captivity.
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
It might be of some concern to shareholders to see the Charles River Laboratories International, Inc. ( NYSE:CRL...
Charles River (CRL) launches cloud-based platform Apollo which enhances decision making abilities by providing real-time Toxicology study data.
Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.
WILMINGTON, Mass., March 13, 2023--Charles River Laboratories To Present At Barclays Global Healthcare Conference
WILMINGTON, Mass., March 13, 2023--Charles River launches Apollo, an intuitive customer platform that provides secure cloud-based access to real-time toxicology study data.
WILMINGTON, Mass., March 09, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available immediately in Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP)-grade.
Investors who take an interest in Charles River Laboratories International, Inc. ( NYSE:CRL ) should definitely note...
Charles River Laboratories International ( NYSE:CRL ) Full Year 2022 Results Key Financial Results Revenue: US$3.98b...
Charles River Laboratories said on Wednesday that it had received a subpoena from the U.S. Department of Justice over an investigation into the supply of non-human primates from Cambodia, which are a part of the animal research services that the company offers to drug developers. The DoJ had in November charged members of an international primate smuggling ring with multiple felonies for their role in bringing wild long-tailed macaques into the United States. Charles River expects constraints on the supply of monkeys to reduce its consolidated revenue growth forecast by about 200 to 400 basis points this year.
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.